About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
How to Integrate CAR-T in the Clinical Scenario of Multiple Myeloma
By
SOHO Italy 1st Clinical and Biological School of CAR-T
FEATURING
Claudio Cerchione
May 2, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
32:57
Merck Oncology
Case Studies Discussion on R/R cHL: Treatment Selection for Certain …
Feat.
W. Donnellan,
L. Leslie
Featured Video
06:53
Sanofi
Geographic and Socioeconomic Disparities in HCT Access for MM: Impac…
Feat.
L. Costa
Related Content
AUTOPLAY
ON
06:56
Sanofi
Autologous HCT in Older Adults with MM: Eligibility Assessment
Feat.
T. Wildes
06:53
Sanofi
Geographic and Socioeconomic Disparities in HCT Access for MM: Impac…
Feat.
L. Costa
04:08
CancerGRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
24:19
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…
Feat.
P. Richardson
10:29
Mary Kwok
Moving to Quadruplets in NDMM
31:36
Nebraska Oncology Society
ASCO 2022 on Moving Toward a Cure in Myeloma: The Role of MRD Testing
Feat.
A. Nooka
34:28
2022 Community Oncology Conference
Treatment Conundrums in Myeloma
Feat.
S. Giralt
17:59
Parameswaran Hari
Delivering the Best Initial Treatment for Myeloma: Induction Therapy…
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
15:12
Yale Cancer Center
ASH 2021: Cellular Therapies in Myeloma
Feat.
N. Bar
10:40
Claudio Cerchione
Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT…
26:05
SOHO Italy 1st School of Multiple Myeloma
Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…
Feat.
C. Cerchione
16:57
SOHO Italy 1st School of Multiple Myeloma
Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …
Feat.
C. Cerchione
15:57
SOHO 3rd Italian Conference
SOHO Italy 2021 on CAR T in MM: Preliminary Data and Perspectives
Feat.
C. Cerchione
17:47
SOHO 3rd Italian Conference
SOHO Italy 2021 on MM: State of the Art Therapy in Europe
Feat.
C. Cerchione
01:29
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…
Feat.
C. Cerchione
04:29
ecancer
EHA 2022 on a Phase III GMMG-HD7 Trial: Isa-RVd as Induction Therapy…
Feat.
E. Mai
23:18
Oncology Data Advisor
Can Diet and Nutrition Impact Multiple Myeloma Outcomes?
Feat.
U. Shah,
R. Banerjee
19:13
SOHO Italy 1st School of Multiple Myeloma
Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?
Feat.
C. Cerchione
15:24
SOHO 3rd Italian Conference
SOHO Italy 2021 on R/R MM Treatment in Europe
Feat.
C. Cerchione
